Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Indolent Non-Hodgkin Lymphoma × obinutuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 34 Lymphoma, Follicular 19 Lymphoma, Mantle-Cell 15 Lymphoma, Non-Hodgkin 9 Lymphoma, Large B-Cell, Diffuse 9 Lymphoma, B-Cell, Marginal Zone 9 Lymphoma 5 Neoplasms 4 Lymphoma, B-Cell 3 Leukemia 3 Waldenstrom Macroglobulinemia 2 Neoplasm, Residual 2 Leukemia, Hairy Cell 2 Leukemia, B-Cell 2 Recurrence 1 Oncology Patients Receiving Chemotherapy 1 Neoplasm Metastasis 1 Indolent Non-Hodgkin's Lymphoma 1 Indolent Non-Hodgkin Lymphoma 1 Disease 1 Dendritic Cell Sarcoma, Interdigitating 1 Cytokine Release Syndrome 1 Carcinoma, Non-Small-Cell Lung 1 Burkitt Lymphoma 1

Interventions

obinutuzumab 1 ibrutinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02689869 2021-05-07

Alternative

Ludwig-Maximilians - University of Munich

Phase 2 Unknown

Indolent Non-Hodgkin Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡